Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
InMode Ltd. (NASDAQ:INMD – Get Rating) was the target of some unusual options trading activity on Tuesday. Stock traders purchased 8,305 call options on the stock. This represents an increase of approximately 113% compared to the average volume of 3,906 call options.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. lifted its stake in shares of InMode by 7.9% during the 1st quarter. Russell Investments Group Ltd. now owns 41,743 shares of the healthcare company’s stock valued at $1,538,000 after buying an additional 3,047 shares in the last quarter. Swiss National Bank lifted its stake in shares of InMode by 8.2% during the 1st quarter. Swiss National Bank now owns 209,600 shares of the healthcare company’s stock valued at $7,736,000 after buying an additional 15,800 shares in the last quarter. Level Four Advisory Services LLC purchased a new stake in shares of InMode during the 1st quarter valued at approximately $448,000. Parametrica Management Ltd purchased a new stake in shares of InMode during the 1st quarter valued at approximately $539,000. Finally, Guild Investment Management Inc. purchased a new stake in shares of InMode during the 1st quarter valued at approximately $930,000. 54.93% of the stock is currently owned by hedge funds and other institutional investors.
InMode Stock Up 2.6 %
INMD stock traded up $0.95 during trading on Tuesday, reaching $37.73. The stock had a trading volume of 1,786,902 shares, compared to its average volume of 1,817,357. InMode has a one year low of $20.60 and a one year high of $73.75. The company’s 50 day moving average is $34.71 and its two-hundred day moving average is $31.06. The company has a market capitalization of $3.14 billion, a price-to-earnings ratio of 18.23 and a beta of 2.20.
InMode (NASDAQ:INMD – Get Rating) last issued its quarterly earnings data on Thursday, October 27th. The healthcare company reported $0.58 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.63 by ($0.05). InMode had a return on equity of 39.52% and a net margin of 40.93%. The firm had revenue of $121.23 million during the quarter, compared to the consensus estimate of $120.70 million. As a group, research analysts predict that InMode will post 2.09 earnings per share for the current fiscal year.
Analyst Ratings Changes
INMD has been the topic of several recent analyst reports. Jefferies Financial Group started coverage on shares of InMode in a report on Wednesday, October 12th. They issued a “buy” rating and a $40.00 target price on the stock. TheStreet lowered shares of InMode from a “b-” rating to a “c+” rating in a report on Tuesday, September 20th. Four analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $46.60.
InMode Company Profile
(Get Rating)
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.
Read More
- Get a free copy of the StockNews.com research report on InMode (INMD)
- What is Market Structure in Trading?
- Institutional Selling Is No Headwind For Nike
- Mullen Automotive Shifts Into Higher Gear
- Why the Cracker Barrel Selloff Looks Overcooked
- It’s Still Too Soon to Shop for Kohl’s Stock
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider InMode, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and InMode wasn’t on the list.
While InMode currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Complete the form below to receive the latest headlines and analysts’ recommendations for your stocks with our free daily email newsletter:
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
As Featured By:
326 E 8th St #105, Sioux Falls, SD 57103
contact@marketbeat.com
(844) 978-6257
© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.
